NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

ACE Inhibitors

; ; .

Author Information

Last Update: July 8, 2021.

Continuing Education Activity

ACE inhibitors are a medication class used to treat and manage hypertension, which is a significant risk factor for coronary disease, heart failure, stroke, and a host of other cardiovascular conditions. Most cases are primary and not attributable to any specific etiology. This activity reviews the indications, contraindications, mechanism, adverse events, and other key elements of ACE inhibitor therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with hypertension and its related conditions and sequelae.

Objectives:

  • Identify the mechanism of action of ACE inhibitors.
  • Summarize the adverse effects of ACE inhibitors.
  • Outline the classic indications for initiating ACE inhibitor therapy.
  • Review interprofessional team approach using evidence-based medicine and patient-centered approach to improve patient outcomes.
Access free multiple choice questions on this topic.

Indications

FDA Approved Uses

1. Angiotensin-converting enzyme (ACE) inhibitors are useful as adjunctive therapy in systolic heart failure (HF). HF guidelines recommend ACE inhibitors to help prevent HF in patients with a reduced ejection fraction (EF) who also have a history of myocardial infarction (MI), and to prevent HF in any patient with a reduced ejection fraction (EF), or to treat patients with HF, and reduced EF.

2. ACE inhibitors can be used for the treatment of hypertension (HTN) either alone or in conjunction with other antihypertensives in adults or children greater than six years old. Hypertension guidelines recommend the initiation of ACE inhibitors for the management of HTN to lower blood pressure (BP). Treatment recommendations in the following populations according to the American College of Cardiology are[1]:

  • Patients with daytime BP out of the office at greater than 135 mmHg systolic or greater than 85 mmHg diastolic; this is substitutable with office blood pressure readings of over 140/90 mmHg
  • Patients with an in-office or out of office BP exceeding 130 mmHg systolic or over 80 mmHg diastolic and the addition of the following factors:
    • History of cardiovascular disease
    • Type 2 diabetes mellitus
    • Chronic kidney disease
    • Age 65 or older

3. Patients with chronic kidney disease (CKD) and HTN:

  • Regardless of race or diabetes mellitus status, ACE inhibitors are recommended as initial therapy to improve kidney outcomes.
  • In the non-Black population with diabetes mellitus and without CKD, initial antihypertensive therapy should include either thiazide diuretic, calcium channel blocker (CCB), ACE inhibitor, or angiotensin receptor blocker (ARB).
  • In the Black population with diabetes mellitus and without CKD, initial antihypertensive therapy should include a thiazide diuretic or CCB instead of an ACE inhibitor or ARB.

4. Patients with coronary artery disease (CAD) and HTN:

  • ACE inhibitors are recommended as part of a regimen in patients with HTN and chronic stable angina if there is a history of left ventricular dysfunction, diabetes mellitus, or CKD.

5. Patients with ST-elevated myocardial infarction (STEMI):

  • ACE inhibitors should be initiated within 24 hours of all STEMI, specifically in patients with anterior MI, heart failure, or left ventricular (LV) ejection fraction (EF) of 40% or less.
  • ACE inhibitors show efficacy in treatment due to the overall reduction of mortality in multiple disease states. There is evidence of mortality benefit in patients with hypertension, heart failure, Acute MI, and diabetes mellitus.[2][3][4]

Non-FDA Uses

ACE inhibitors may delay the progression of nephropathy and reduce the risks of cardiovascular events in hypertensive patients with diabetes type I and type II. The addition of an ACE inhibitor has shown a significant reduction in serum creatinine in both hypertensive patients and normotensive patients with albuminuria. ACE inhibitor therapy has shown a significant decrease in the progression of diabetic nephropathy.[5][6]

Mechanism of Action

The angiotensin-converting-enzyme is involved in the renin-angiotensin-aldosterone system (RAAS; media item 1) and stimulates the conversion of angiotensin I to angiotensin II. ACE inhibitors are competitive inhibitors of ACE, which prevent the conversion of angiotensin I to angiotensin II. Angiotensin II acts as a potent vasoconstrictor that, when inhibited, can reduce blood pressure by dilating vessels and decreasing aldosterone secretion.[7][2][3]

It is essential to understand the role of the RAS hormonal system in depth to appreciate the therapeutic effects of ACE inhibitors and understand why this is a target for hypertensive therapy. Initially, afferent arteriole juxtaglomerular cells synthesize prorenin, which is actively cleaved to renin. Angiotensinogen produced from the liver is then cleaved by renin to form angiotensin I. The angiotensin I molecule is converted to angiotensin II by ACE. Angiotensin II is a molecule that has significant actions on various systems. Initially, Angiotensin II induces vasoconstriction, which ultimately increases systemic blood pressure.[8] Even further, Angiotensin II stimulates the adrenal cortex and the pituitary to produce aldosterone and Anti-diuretic hormone (ADH), respectively. Aldosterone induces sodium reabsorption and, in turn, water reabsorption through internal mineralocorticoid receptor activity [9]. Antidiuretic Hormone increases the synthesis of aquaporin-2 channels in the collecting duct inducing selective reabsorption of water. Actions of angiotensin-II and aldosterone lead to adverse cardiac remodeling. ACE inhibitors prevent adverse cardiac remodeling by reducing the level of angiotensin-II and aldosterone.[10]

Administration

ACE inhibitors are most commonly administered as oral agents, but intravenous forms are available. These medications most commonly end with the suffix '-pril.' Examples include lisinopril, ramipril, and captopril.

Depending on the Chemical Structure, ACE Inhibitors are Classified into Three Groups:

  • Sulfhydryl-containing ACE inhibitor. Captopril –  Hypertension therapy is 25 mg, either BID or TID, with a maximum of 450 mg. Heart failure therapy is 6.25 mg TID, with a maximum of 450 mg.
  • Phosphorus-containing ACE inhibitor. Fosinopril – Hypertension therapy dosing is 10 mg, increasing to a maximum dose of 80 mg. May split into two equal doses during the day to control blood pressure. Heart failure therapy is 5 to 10 mg daily to a maximum dose of 40 mg.
  • Dicarboxylic-containing ACE inhibitors: see table

General Dosing Information

All of the ACE inhibitors are prescribed orally, except for enalapril, which can be given intravenously. Enalapril's IV dosage is initially 0.625 to 1.25 mg every 6 hours. Dosage titration up can be to 5 mg IV every 6 hours. Geriatric dosing should definitely initiate at the lower end of the adult dosing regimen.

There should be a dosage decrease in patients with heart failure, salt-depleted patients, and/or renal impairment. 

Lisinopril and captopril are the only ACE inhibitors that do not have to be activated in the body to be effective. All the other ACE inhibitors are prodrugs and require activation. Most reach peak serum levels within 1 hour after ingestion. Since most of the activation occurs in the liver, a non-prodrug form is preferable in patients with underlying liver issues.[11]

Adverse Effects

Most common adverse reactions:

  • Dry Cough (10% to 20%)
  • Dizziness (12% to 19%)
  • Hypotension (7% to 11%)
  • Increased BUN and creatinine (2% to 11%)
  • Syncope (5% to 7%)
  • Hyperkalemia (2% to 6%)

Dry Cough: Commonly, patients on ACE inhibitors have reported dry cough between the one week of initiation up to six months. Some sources cite up to one year after initiation. Discontinuing therapy usually resolves the cough 1 to 4 days after, but it can be prolonged up to a month.[12] The concern for dry cough with therapy initiation is a decrease in medication adherence. Additionally, there is an increased propensity to develop bronchospasm in these patients.[13] 

ACE metabolizes bradykinin and other local molecules. Inhibiting ACE in the lung increases the concentration of kinins, causing bronchial irritation.[14] After discontinuation of ACE inhibitor therapy, an angiotensin receptor blocker (ARB) can be initiated as an alternate therapy. ARB’s have a lower incidence of cough recurrence compared to reinitiating ACE inhibitor therapy.[15] If cough recurs on ARB therapy, switch to a different drug class entirely.

Angioedema: Angioedema is a rare but potentially life-threatening side effect of ACE inhibitor use. Angioedema is an adverse drug reaction characterized by swelling of the face, lips, and upper airway in an episodic nature. The inflammation creates difficulty in the patient’s ability to maintain an airway; therefore, endotracheal intubation is necessary to secure the airway. The mechanism of angioedema is thought to be through an extensive accumulation of bradykinins in select individuals. Bradykinin induces prominent vasodilation and plasma extravasation into the local tissue. Therefore, the primary treatment of ACE inhibitor-induced angioedema is the discontinuation of ACE inhibitor therapy. It is also suggested to avoid ACE inhibitor therapy in individuals with hereditary angioedema or a history of angioedema episodes.

Hyperkalemia: Hyperkalemia from ACE inhibitors is a direct result of its mechanism of action. The blockade of angiotensin II prevents the downstream secretion of aldosterone. Aldosterone causes reabsorption of sodium and, subsequently, water. Consequently, protons and potassium get secreted into the urine. Without the secretion of potassium through aldosterone, potassium can easily increase in patients on ACE inhibitors.[16] Co-morbidities that decrease kidney function or medications that cause potassium retention can increase the risk of hyperkalemia.

Increased BUN and creatinine: A slight reduction of glomerular filtration rate (GFR) is common when initiating therapy. Patients with heart failure, chronic kidney disease, and bilateral renal artery stenosis who have poor renal perfusion can further reduce GFR, which mandates discontinuation of ACE-Inhibitor therapy.[17]

Hypotension: Hypotension can cause intolerance to therapy leading to discontinuation in a small population of patients, which is more common in patients with increased renin baseline concentrations. Allowing repletion of fluids and discontinuing diuretic medication before therapy can minimize hypotensive episodes.[18]

Dizziness: Dizziness is a common adverse drug reaction of ACE inhibitor therapy which can be mitigated by adequate volume status and avoiding concomitant diuretic therapy.[4][19]

Postmarketing surveillance: Significant adverse events are reported in less than one percent population in post-marketing surveillance. These adverse drug reactions include anaphylactoid reactions, cardiac arrest, cutaneous pseudolymphoma, eosinophilic pneumonitis, hepatic necrosis, hyponatremia, intestinal angioedema, malignant neoplasm of lung, pulmonary embolism, systemic lupus erythematosus, Steven-Johnson Syndrome, toxic epidermal necrolysis, and transient ischemic attack.

Contraindications

Absolute Contraindications

  • Hypersensitivity reactions- ACE inhibitors are contraindicated in a patient with a history of hypersensitivity to any ACE inhibitor or component of the formulation, angioedema related to previous treatment with ACE inhibitor, idiopathic or hereditary angioedema, or current use of aliskiren in a patient with diabetes mellitus. Also, consider drugs with cross-reactivity with ACE inhibitors.[20][21]
  • Pregnancy -The use of drugs that inhibit the renin-angiotensin system correlates with teratogenic effects such as oligohydramnios, decreased fetal renal function, anuria, renal failure, skull hypoplasia, and death. The proposed mechanism behind oligohydramnios is evident at the level of the fetal kidney. The low-pressure hemodynamics of the fetus becomes easily disrupted with a decreased amount of angiotensin II. Fetal renal pressure becomes lower, reducing the ability to maintain GFR, leading to oligohydramnios and anuria.[22]

Relative Contraindications

Use with great caution in the following situations:

  • Patients with abnormal renal function: ACE inhibitors can cause elevation of potassium and worsen renal function in patients already on ACE inhibitors. If the patient has an abnormal but stable renal function, close monitoring is required on an ACE inhibitor. If the renal function starts to decline, the clinician should discontinue the ACE inhibitor immediately.
  • Patients with aortic valve stenosis: ACE inhibitors reduce afterload and lead to severe hypotension, so these patients should not receive ACE inhibitors. 
  • Patient with hypovolemia: ACE inhibitors can worsen dehydration and hypovolemia, so these patients should not receive treatment with ACE inhibitors.

Monitoring

  • Typical parameters to monitor are renal function, i.e., Blood Urea Nitrogen(BUN), serum creatinine, and electrolytes such as potassium.[23]
  • If a patient has collagen vascular disease and/or renal impairment, periodically monitor complete blood count with differential to evaluate kidney erythropoietin production.
  • In patients with hypotensive effects within 1 to 3 hours of initial dose or increased dosages or preexisting hepatic impairment, consider baseline hepatic function tests.
  • A white and red blood cell counts are necessary to evaluate for rare side effects of anemia, neutropenia, agranulocytosis, and thrombocytopenia.[24]

Toxicity

  • When used at therapeutic doses, the risk of toxicity is rare. Toxicity is more likely when the drug is used in combination with other antihypertensive drugs or at supratherapeutic doses. Captopril is the only ACE inhibitor to penetrate the blood-brain barrier and potentially cause confusion and lethargy.[25] Combining ACE inhibitors with other antihypertensive drugs can increase side effects like hyperkalemia, hypotension, and renal failure. Precaution is required when the patient is given an ACE inhibitor and already receives a potassium-sparing diuretic, NSAIDs, cyclosporine, and anticoagulants.
  • For the majority of patients, the effects of poisoning are mild, and close observation is required. Hospital admission is indicated when symptoms and signs are more severe. Derranged hemodynamic parameters may require supportive therapy with intravenous fluids and inotropic support.[25]

Enhancing Healthcare Team Outcomes

Clinicians widely use ACE inhibitors in medicine to treat hypertension, heart failure, and patients with chronic kidney disease. While effective, healthcare workers (nurse practitioners, physicians, and pharmacists) who prescribe these agents should be aware of their adverse drug reactions and contraindications. Patients also need to be monitored for their renal function and electrolyte concentrations regularly. Healthcare providers should be aware that these agents can produce a chronic dry cough. The clinician should try another class of antihypertensive medication if the patient experiences a dry cough.[7][26][27][28] 

Even though ACE inhibitors are among the oldest drug classes available, there is a threat that familiarity can lead to carelessness. That is why, like any other drug, these agents require the oversight and coordination of an interprofessional team. Pharmacists need to verify that dosing is appropriate and check for potential drug interactions.[29] Nurses should take blood pressure at every visit and chart it accurately, so the clinician can determine if dosing or other changes are required. Nurses can monitor for potential signs of pregnancy and promptly inform the clinician if the patient is pregnant as ACE inhibitors are absolutely contraindicated in pregnancy.[30] The clinician must remain informed by these findings from the other interprofessional healthcare team members to take corrective action if necessary. In summary, the interprofessional team approach using evidence-based medicine and patient-centered care correlates with reduced morbidity and mortality in patients receiving ACE inhibitor therapy.[31] [Level 5]

Review Questions

Illustration of Renin-Angiotensin Aldosterone system (RAAS) pathway

Figure

Illustration of Renin-Angiotensin Aldosterone system (RAAS) pathway. Contribute Austin Cusick and Amandeep Goyal, MD

References

1.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. [PubMed: 29133356]
2.
Knežević T, Gellineo L, Jelaković A, Premužić V, Dika Ž, Laganović M, Jelaković B. Treatment of Hypertension Induced Albuminuria. Curr Pharm Des. 2018;24(37):4404-4412. [PubMed: 30479206]
3.
Hradec J. Pharmacological therapy for chronic heart failure. Vnitr Lek. 2018 Fall;64(9):853-859. [PubMed: 30441998]
4.
Leru PM, Anton VF, Bumbea H. Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen. Allergy Asthma Clin Immunol. 2018;14:69. [PMC free article: PMC6201569] [PubMed: 30386386]
5.
Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994 Jan 26;271(4):275-9. [PubMed: 8295285]
6.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-62. [PubMed: 8413456]
7.
Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018 Nov 14;11:CD008170. [PMC free article: PMC6516995] [PubMed: 30480768]
8.
Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017 Oct;94:317-325. [PubMed: 28772209]
9.
Silva P, Brown RS, Epstein FH. Adaptation to potassium. Kidney Int. 1977 Jun;11(6):466-75. [PubMed: 327141]
10.
Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010 Apr;21(2):339-52. [PubMed: 20380974]
11.
Williams B. Drug discovery in renin-angiotensin system intervention: past and future. Ther Adv Cardiovasc Dis. 2016 Jun;10(3):118-25. [PMC free article: PMC5933671] [PubMed: 27126389]
12.
Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Br J Clin Pharmacol. 1995 Nov;40(5):423-9. [PMC free article: PMC1365187] [PubMed: 8703645]
13.
Lunde H, Hedner T, Samuelsson O, Lötvall J, Andrén L, Lindholm L, Wiholm BE. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994 Jan 01;308(6920):18-21. [PMC free article: PMC2539116] [PubMed: 8298346]
14.
Malini PL, Strocchi E, Zanardi M, Milani M, Ambrosioni E. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet. 1997 Jul 05;350(9070):15-8. [PubMed: 9217714]
15.
Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008 Jan 01;148(1):16-29. [PubMed: 17984484]
16.
Kifor I, Moore TJ, Fallo F, Sperling E, Chiou CY, Menachery A, Williams GH. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology. 1991 Aug;129(2):823-31. [PubMed: 1855477]
17.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13;160(5):685-93. [PubMed: 10724055]
18.
Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW, Young JB, Probstfield J. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J. 1996 Feb;131(2):350-5. [PubMed: 8579032]
19.
Sachs B, Meier T, Nöthen MM, Stieber C, Stingl J. [Drug-induced angioedema : Focus on bradykinin]. Hautarzt. 2018 Apr;69(4):298-305. [PubMed: 29392343]
20.
Wilkins B, Hullikunte S, Simmonds M, Sasse A, Larsen P, Harding SA. Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction. Heart Lung Circ. 2019 Feb;28(2):257-262. [PubMed: 29523466]
21.
Shaikh A. A Practical Approach to Hypertension Management in Diabetes. Diabetes Ther. 2017 Oct;8(5):981-989. [PMC free article: PMC5630564] [PubMed: 28929319]
22.
Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int. 2010 Mar;77(5):400-6. [PubMed: 19924102]
23.
Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):55-64. [PubMed: 16470693]
24.
DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Med Toxicol. 1986 Mar-Apr;1(2):122-41. [PubMed: 3023783]
25.
Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. J Hum Hypertens. 1995 Sep;9(9):711-5. [PubMed: 8551483]
26.
Alzahrani T, Tiu J, Panjrath G, Solomon A. The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. Ther Adv Cardiovasc Dis. 2018 Dec;12(12):351-359. [PMC free article: PMC6266248] [PubMed: 30442080]
27.
Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N., Interdisciplinary Chronic Disease Collaboration. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury. JAMA Intern Med. 2018 Dec 01;178(12):1681-1690. [PMC free article: PMC6583606] [PubMed: 30422153]
28.
Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, Vecchio M, Tognoni G, Craig JC, Pellegrini F, Lucisano G, Hegbrant J, Ariano R, Lamacchia O, Sasso A, Morano S, Filardi T, De Cosmo S, Pugliese G, Procaccini DA, Gesualdo L, Palasciano G, Johnson DW, Tonelli M, Strippoli GFM., Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators. The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial. J Am Soc Nephrol. 2018 Dec;29(12):2890-2899. [PMC free article: PMC6287867] [PubMed: 30420421]
29.
Mansur JM. Medication Safety Systems and the Important Role of Pharmacists. Drugs Aging. 2016 Mar;33(3):213-21. [PubMed: 26932714]
30.
Simonetti V, Comparcini D, Tomietto M, Pavone D, Flacco ME, Cicolini G. Effectiveness of a family nurse-led programme on accuracy of blood pressure self-measurement: A randomised controlled trial. J Clin Nurs. 2021 Aug;30(15-16):2409-2419. [PubMed: 33872417]
31.
Mao CT, Liu MH, Hsu KH, Fu TC, Wang JS, Huang YY, Yang NI, Wang CH. Effect of multidisciplinary disease management for hospitalized heart failure under a national health insurance programme. J Cardiovasc Med (Hagerstown). 2015 Sep;16(9):616-24. [PubMed: 25105284]
Copyright © 2021, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK430896PMID: 28613646

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...